European Biotech Acquisition Valuation
Based on Macroaxis valuation methodology, the firm cannot be evaluated at this time. European Biotech Acq prevailing Real Value cannot be determined due to lack of data. The current price of European Biotech Acq is $0.0. Our model computes the value of European Biotech Acq from reviewing the firm fundamentals such as Price To Earning of 66.40 X, price to book of 1.34 X, and Shares Owned By Institutions of 72.30 % as well as analyzing its technical indicators and probability of bankruptcy.
European Biotech Total Value Analysis
European Biotech Acquisition is currently forecasted to have valuation of 164.04 M with market capitalization of 183.5 M, debt of , and cash on hands of 308.1 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the European Biotech fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
164.04 M | 183.5 M | 308.1 K |
European Biotech Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The latest return on assets of European indicates not a very effective usage of assets in January.European Biotech Ownership Allocation
The market capitalization of European Biotech Acq is $183.5 Million. The majority of European Biotech Acquisition outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in European Biotech Acq to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in European Biotech. Please pay attention to any change in the institutional holdings of European Biotech Acquisition as this could imply that something significant has changed or is about to change at the company. Please take into account that even companies with profitable outlook can generate negative future returns on their equity. If the true value of the firm is less than the current market value, you may not be able generate positive returns on investment in the long run.European Biotech Profitability Analysis
Net Income was 342.89 K with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates European Biotech's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in European Biotech and how it compares across the competition.
European Biotech Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 12.8 M | |
| Quarterly Earnings Growth Y O Y | -0.588 | |
| Retained Earnings | -8.1 M |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in European Stock
If you are still planning to invest in European Biotech Acq check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the European Biotech's history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |